Can tumor genetics predict survival in nasopharyngeal cancer?

NCT ID NCT07741110

Completed Knowledge-focused Sponsor: Hellenic Cooperative Oncology Group Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study looks back at tissue samples from patients with nasopharyngeal carcinoma who took part in an earlier treatment trial. Researchers are using advanced genetic testing and protein analysis to look for markers linked to how long patients survive. The goal is to better understand which biological factors may influence outcomes and potentially guide more personalized treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: This analysis could identify genetic or protein markers that help predict which patients with nasopharyngeal carcinoma are more likely to survive, potentially guiding more personalized treatment decisions in the future.
What could go wrong: Because this is a retrospective analysis of a previous trial, the findings may not be definitive and could fail to identify reliable markers. The small sample size and use of stored tissue samples may also limit the accuracy and generalizability of the results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA (NPC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.